A Single-arm, Multicenter, Exploratory Study of Adebrelimab Combined With Apatinib and Systemic Chemotherapy for Initially Unresectable Biliary Tract Cancer

This is an exploratory and prospective study, with the research subjects being patients with initially untreated and unresectable biliary tract tumors. The efficacy and safety of the treatment regimen consisting of Adebrelimab monoclonal antibody combined with targeted therapy and systemic chemotherapy were investigated.

NCT Number	NCT07135544
Lead Sponsor	Yongjun Chen
Conditions	Biliary Tract Cancer, Biliary Tract Cancer (CCA)
Enrollment	37 participants
Start Date	2025-08-14
Primary Completion	2027-06-30 (estimated)
Study Completion	2028-12-30 (estimated)
Updated on ClinicalTrials.gov	2025-08-22